# Coursera, Inc.: financial statements, quarterly

COUR · NYSE · CIK 1651562 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cour.md) · [Financials](/companies/cour/financials.md) · [Filings](/companies/cour/filings.md) · [Insiders](/companies/cour/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cour/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [166](/filings/0001651562-24-000058.md) | [169 d](/filings/0001651562-26-000015.md) | [169](/filings/0001651562-25-000035.md) | [170](/filings/0001651562-25-000049.md) | [176](/filings/0001651562-25-000061.md) | [179 d](/filings/0001651562-26-000015.md) | [179](/filings/0001651562-26-000030.md) | [187](/filings/0001651562-26-000063.md) | [194](/filings/0001651562-25-000061.md) | [197 d](/filings/0001651562-26-000015.md) | [196](/filings/0001651562-26-000030.md) | [299](/filings/0001651562-26-000063.md) |
| Cost of revenue | $m | [82.3](/filings/0001651562-24-000058.md) | [79.6 d](/filings/0001651562-26-000015.md) | [79.6](/filings/0001651562-25-000035.md) | [80.1](/filings/0001651562-25-000049.md) | [79.9](/filings/0001651562-25-000061.md) | [83.7 d](/filings/0001651562-26-000015.md) | [81.4](/filings/0001651562-26-000030.md) | [84.4](/filings/0001651562-26-000063.md) | [88.2](/filings/0001651562-25-000061.md) | [90.1 d](/filings/0001651562-26-000015.md) | [87.1](/filings/0001651562-26-000030.md) | [125](/filings/0001651562-26-000063.md) |
| Gross profit | $m | [83.3](/filings/0001651562-24-000058.md) | [89.4 d](/filings/0001651562-26-000015.md) | [89.5](/filings/0001651562-25-000035.md) | [90.2](/filings/0001651562-25-000049.md) | [96.2](/filings/0001651562-25-000061.md) | [95.5 d](/filings/0001651562-26-000015.md) | [97.9](/filings/0001651562-26-000030.md) | [103](/filings/0001651562-26-000063.md) | [106](/filings/0001651562-25-000061.md) | [107 d](/filings/0001651562-26-000015.md) | [109](/filings/0001651562-26-000030.md) | [173](/filings/0001651562-26-000063.md) |
| Research and development | $m | [37.6](/filings/0001651562-24-000058.md) | [37.4 d](/filings/0001651562-26-000015.md) | [34.6](/filings/0001651562-25-000035.md) | [33.7](/filings/0001651562-25-000049.md) | [31.6](/filings/0001651562-25-000061.md) | [32.2 d](/filings/0001651562-26-000015.md) | [29.5](/filings/0001651562-26-000030.md) | [29.3](/filings/0001651562-26-000063.md) | [30.0](/filings/0001651562-25-000061.md) | [32.8 d](/filings/0001651562-26-000015.md) | [31.3](/filings/0001651562-26-000030.md) | [43.7](/filings/0001651562-26-000063.md) |
| Operating income | $m | [(39.6)](/filings/0001651562-24-000058.md) | [(28.6) d](/filings/0001651562-26-000015.md) | [(29.8)](/filings/0001651562-25-000035.md) | [(31.2)](/filings/0001651562-25-000049.md) | [(21.7)](/filings/0001651562-25-000061.md) | [(30.5) d](/filings/0001651562-26-000015.md) | [(14.4)](/filings/0001651562-26-000030.md) | [(15.1)](/filings/0001651562-26-000063.md) | [(15.6)](/filings/0001651562-25-000061.md) | [(32.3) d](/filings/0001651562-26-000015.md) | [(25.3)](/filings/0001651562-26-000030.md) | [(84.7)](/filings/0001651562-26-000063.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.0](/filings/0001651562-24-000058.md) | [1.3 d](/filings/0001651562-26-000015.md) | [0.8](/filings/0001651562-25-000035.md) | [1.0](/filings/0001651562-25-000049.md) | [1.5](/filings/0001651562-25-000061.md) | [(2.3) d](/filings/0001651562-26-000015.md) | [1.5](/filings/0001651562-26-000030.md) | [0.8](/filings/0001651562-26-000063.md) | [0.8](/filings/0001651562-25-000061.md) | [2.0 d](/filings/0001651562-26-000015.md) | [1.4](/filings/0001651562-26-000030.md) | [2.1](/filings/0001651562-26-000063.md) |
| Net income | $m | [(32.1)](/filings/0001651562-24-000058.md) | [(20.4) d](/filings/0001651562-26-000015.md) | [(21.3)](/filings/0001651562-25-000035.md) | [(22.9)](/filings/0001651562-25-000049.md) | [(13.7)](/filings/0001651562-25-000061.md) | [(21.6) d](/filings/0001651562-26-000015.md) | [(7.8)](/filings/0001651562-26-000030.md) | [(7.8)](/filings/0001651562-26-000063.md) | [(8.6)](/filings/0001651562-25-000061.md) | [(26.8) d](/filings/0001651562-26-000015.md) | [(20.5)](/filings/0001651562-26-000030.md) | [(80.4)](/filings/0001651562-26-000063.md) |
| Diluted EPS | $ per share | [(0.21)](/filings/0001651562-24-000058.md) | not reported | [(0.14)](/filings/0001651562-25-000035.md) | [(0.15)](/filings/0001651562-25-000049.md) | [(0.09)](/filings/0001651562-25-000061.md) | not reported | [(0.05)](/filings/0001651562-26-000030.md) | [(0.05)](/filings/0001651562-26-000063.md) | [(0.05)](/filings/0001651562-25-000061.md) | not reported | [(0.12)](/filings/0001651562-26-000030.md) | [(0.34)](/filings/0001651562-26-000063.md) |
| Basic EPS | $ per share | [(0.21)](/filings/0001651562-24-000058.md) | not reported | [(0.14)](/filings/0001651562-25-000035.md) | [(0.15)](/filings/0001651562-25-000049.md) | [(0.09)](/filings/0001651562-25-000061.md) | not reported | [(0.05)](/filings/0001651562-26-000030.md) | [(0.05)](/filings/0001651562-26-000063.md) | [(0.05)](/filings/0001651562-25-000061.md) | not reported | [(0.12)](/filings/0001651562-26-000030.md) | [(0.34)](/filings/0001651562-26-000063.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [507](/filings/0001651562-23-000027.md) | [656](/filings/0001651562-26-000015.md) | [725](/filings/0001651562-24-000035.md) | [709](/filings/0001651562-24-000049.md) | [719](/filings/0001651562-24-000058.md) | [726](/filings/0001651562-26-000015.md) | [748](/filings/0001651562-25-000035.md) | [775](/filings/0001651562-25-000049.md) | [798](/filings/0001651562-25-000061.md) | [793](/filings/0001651562-26-000063.md) | [790](/filings/0001651562-26-000030.md) | [872](/filings/0001651562-26-000063.md) |
| Current assets | $m | [829](/filings/0001651562-23-000027.md) | [832](/filings/0001651562-25-000013.md) | [833](/filings/0001651562-24-000035.md) | [821](/filings/0001651562-24-000049.md) | [821](/filings/0001651562-24-000058.md) | [831](/filings/0001651562-26-000015.md) | [854](/filings/0001651562-25-000035.md) | [882](/filings/0001651562-25-000049.md) | [897](/filings/0001651562-25-000061.md) | [898](/filings/0001651562-26-000063.md) | [893](/filings/0001651562-26-000030.md) | [1,221](/filings/0001651562-26-000063.md) |
| Total assets | $m | [914](/filings/0001651562-23-000027.md) | [921](/filings/0001651562-25-000013.md) | [916](/filings/0001651562-24-000035.md) | [904](/filings/0001651562-24-000049.md) | [914](/filings/0001651562-24-000058.md) | [930](/filings/0001651562-26-000015.md) | [951](/filings/0001651562-25-000035.md) | [980](/filings/0001651562-25-000049.md) | [995](/filings/0001651562-25-000061.md) | [1,000](/filings/0001651562-26-000063.md) | [1,001](/filings/0001651562-26-000030.md) | [1,948](/filings/0001651562-26-000063.md) |
| Current liabilities | $m | [296](/filings/0001651562-23-000027.md) | [298](/filings/0001651562-25-000013.md) | [303](/filings/0001651562-24-000035.md) | [316](/filings/0001651562-24-000049.md) | [315](/filings/0001651562-24-000058.md) | [328](/filings/0001651562-26-000015.md) | [335](/filings/0001651562-25-000035.md) | [346](/filings/0001651562-25-000049.md) | [350](/filings/0001651562-25-000061.md) | [358](/filings/0001651562-26-000063.md) | [362](/filings/0001651562-26-000030.md) | [768](/filings/0001651562-26-000063.md) |
| Total liabilities | $m | [301](/filings/0001651562-23-000027.md) | [304](/filings/0001651562-25-000013.md) | [307](/filings/0001651562-24-000035.md) | [319](/filings/0001651562-24-000049.md) | [321](/filings/0001651562-24-000058.md) | [333](/filings/0001651562-26-000015.md) | [341](/filings/0001651562-25-000035.md) | [353](/filings/0001651562-25-000049.md) | [356](/filings/0001651562-25-000061.md) | [364](/filings/0001651562-26-000063.md) | [369](/filings/0001651562-26-000030.md) | [781](/filings/0001651562-26-000063.md) |
| Shareholders' equity | $m | [613](/filings/0001651562-24-000058.md) | [616](/filings/0001651562-26-000015.md) | [609](/filings/0001651562-25-000049.md) | [585](/filings/0001651562-25-000061.md) | [593](/filings/0001651562-25-000061.md) | [597](/filings/0001651562-26-000063.md) | [611](/filings/0001651562-26-000063.md) | [627](/filings/0001651562-26-000063.md) | [640](/filings/0001651562-25-000061.md) | [636](/filings/0001651562-26-000063.md) | [632](/filings/0001651562-26-000063.md) | [1,167](/filings/0001651562-26-000063.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [19.8 d](/filings/0001651562-24-000058.md) | [11.6 d](/filings/0001651562-26-000015.md) | [24.5](/filings/0001651562-25-000035.md) | [23.8 d](/filings/0001651562-25-000049.md) | [27.9 d](/filings/0001651562-25-000061.md) | [19.2 d](/filings/0001651562-26-000015.md) | [33.5](/filings/0001651562-26-000030.md) | [35.5 d](/filings/0001651562-26-000063.md) | [33.9 d](/filings/0001651562-25-000061.md) | [5.8 d](/filings/0001651562-26-000015.md) | [14.6](/filings/0001651562-26-000030.md) | [(19.8) d](/filings/0001651562-26-000063.md) |
| Capital expenditure | $m | [0.3 d](/filings/0001651562-24-000058.md) | [0.1 d](/filings/0001651562-26-000015.md) | [0.1](/filings/0001651562-25-000035.md) | [0.2 d](/filings/0001651562-25-000049.md) | [0.2 d](/filings/0001651562-25-000061.md) | [1.1 d](/filings/0001651562-26-000015.md) | [0.5](/filings/0001651562-26-000030.md) | [0.4 d](/filings/0001651562-26-000063.md) | [0.2 d](/filings/0001651562-25-000061.md) | [0.4 d](/filings/0001651562-26-000015.md) | [0.2](/filings/0001651562-26-000030.md) | [0.3 d](/filings/0001651562-26-000063.md) |
| Share repurchases | $m | [5.4 d](/filings/0001651562-24-000058.md) | [0.0 d](/filings/0001651562-26-000015.md) | [5.6](/filings/0001651562-25-000035.md) | [31.1 d](/filings/0001651562-25-000049.md) | [0.0 d](/filings/0001651562-25-000061.md) | [0.0 d](/filings/0001651562-26-000015.md) | [0.0](/filings/0001651562-25-000035.md) | [0.0 d](/filings/0001651562-26-000063.md) | [0.0 d](/filings/0001651562-25-000061.md) | [0.0 d](/filings/0001651562-26-000015.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [146](/filings/0001651562-23-000027.md) | [149](/filings/0001651562-24-000035.md) | [150](/filings/0001651562-24-000049.md) | [151](/filings/0001651562-24-000058.md) | [156](/filings/0001651562-25-000035.md) | [156](/filings/0001651562-25-000049.md) | [158](/filings/0001651562-25-000061.md) | [161](/filings/0001651562-26-000030.md) | [163](/filings/0001651562-26-000063.md) | [165](/filings/0001651562-25-000061.md) | [169](/filings/0001651562-26-000030.md) | [233](/filings/0001651562-26-000063.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 264,400,000 at 2026-07-29, from the cover of the [10-Q filed 2026-08-05](/filings/0001651562-26-000063.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.